CEP: Career Enhancement Program

CEP:职业提升计划

基本信息

项目摘要

PROJECT SUMMARY – CAREER ENHANCEMENT PROGRAM (CEP) The mission of the Hillman Cancer Center (HCC) Ovarian Cancer (OvCa) SPORE Career Enhancement Program (CEP) is to foster the development of independent translational ovarian cancer researchers who will impact ovarian cancer care. This includes supporting not only outstanding early career scientists, but also experienced investigators wishing to transition their careers into translational ovarian cancer research, or clinical investigators well versed in the design and performance of clinical trials who wish to broaden their translational research experience. The HCC OvCa SPORE is fully committed to diversity and has established collaborations with external institutions to increase the participation of under-represented scientists in the CEP. The CEP will provide funding, access to SPORE resources, and a supportive research environment. Proposals will be solicited annually and use an NIH-style peer-review scoring system to prioritize projects for funding. Projects will be funded for 2 years at $50,000 per year, with half the monies coming from CEP and the other half from institutional funds. The second year of funding will be contingent on progress made during the first year. The CEP Co-Directors, SPORE Executive Committee, and SPORE investigators will participate in the review process, together with Patient Advocates and ad hoc expert revewers when necessary. The final selection of awardees will be made following a second tier review involving the SPORE Internal Advisory Board (IAB). CEP awardees will be matched with an appropriate SPORE mentor and provided full access to the HCC OvCa SPORE Core resources, including tissue specimens and bioinformatics/biostatistical support. The CEP will directly facilitate career development through: i) constructive proposal review and feedback; ii) research training with a mentor chosen from among diverse faculty with broad expertise and experience in academic career development; and iii) access to development programs, including monthly ovarian cancer research group meetings, monthly SPORE meetings, the annual HCC and Magee Womens Research Institute retreats, and the annual SPORE retreat. The CEP will track progress of awardees and ensure that they obtain any needed services from SPORE Cores, and make certain that they are fully integrated into the SPORE program. Awardees will meet regularly with mentors and will be encouraged to participate in courses in clinical and translational research to further enhance their career development. Projects that show the greatest likelihood of impact and translation to the clinic can evolve into future full SPORE projects. Awardees will also be advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE resources to aid in this endeavor. These procedures were developed via a previous joint P50 award that resulted in a 12-fold return on investment for CEP projects. Ultimately, the CEP provides a vital mechanism for achieving the SPORE’s goal of developing the next generation of ovarian cancer researchers committed to overcoming this deadly disease.
项目摘要--职业提升计划(CEP) 希尔曼癌症中心(HCC)、卵巢癌(OvCa)孢子事业促进中心的使命 计划(CEP)是为了促进独立翻译卵巢癌研究人员的发展,他们将 影响卵巢癌治疗。这不仅包括支持杰出的早期职业科学家,而且还包括 有经验的研究人员希望将他们的职业生涯转变为转化性卵巢癌研究,或者 精通临床试验设计和执行的临床研究人员希望扩大他们的 翻译研究经验。肝细胞癌卵母细胞孢子完全致力于多样性,并已建立 与外部机构合作,增加任职人数不足的科学家参与CEP。 CEP将提供资金、获得孢子资源和一个支持性的研究环境。建议书 将每年征集资金,并使用NIH风格的同行审查评分系统来确定资助项目的优先顺序。 项目的资金将为两年,每年50,000美元,其中一半资金来自CEP,另一半来自CEP 其中一半来自机构基金。第二年的资金将视第一年的进展而定。 年。CEP联席董事、孢子执行委员会和孢子调查员将参加 审查流程,必要时与患者权益倡导者和临时专家一起审查。决赛 获奖者的遴选将在涉及孢子内部咨询的第二层审查之后进行 董事会(IAB)。CEP获奖者将与适当的孢子导师匹配,并提供完全访问 肝细胞癌卵胞孢子核心资源,包括组织标本和生物信息学/生物统计学支持。 CEP将通过以下方式直接促进职业发展:一)建设性的提案审查和反馈;二) 从具有广泛专业知识和经验的不同教职员工中挑选一位导师进行研究培训 学术生涯发展;三)获得发展方案,包括每月一次的卵巢癌 研究小组会议、每月孢子会议、每年一次的肝细胞癌和玛吉妇女研究所 休养生息,一年一度的孢子休养生息。CEP将跟踪获奖者的进展,并确保他们获得 孢子芯的任何需要的服务,并确保它们完全整合到孢子中 程序。获奖者将定期与导师会面,并将被鼓励参加临床 和翻译研究,以进一步促进他们的职业发展。展示最伟大的项目 影响和转化到临床的可能性可能演变为未来的全孢子项目。获奖者还将 在为孢子机制以外的资金准备赠款申请时,应酌情给予建议 并获得孢子资源,以帮助这一努力。这些程序是通过 上一次联合P50奖,为CEP项目带来了12倍的投资回报。最终,CEP 为实现孢子发育下一代卵巢的目标提供了重要的机制 癌症研究人员致力于克服这种致命的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRANCESMARY MODUGNO其他文献

FRANCESMARY MODUGNO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRANCESMARY MODUGNO', 18)}}的其他基金

Core B: TCP: Translational Pathology Core
核心 B:TCP:转化病理学核心
  • 批准号:
    10713055
  • 财政年份:
    2023
  • 资助金额:
    $ 7.39万
  • 项目类别:
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes
卵巢癌治疗反应和结果的多组学预测标记
  • 批准号:
    10351697
  • 财政年份:
    2022
  • 资助金额:
    $ 7.39万
  • 项目类别:
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes
卵巢癌治疗反应和结果的多组学预测标记
  • 批准号:
    10678828
  • 财政年份:
    2022
  • 资助金额:
    $ 7.39万
  • 项目类别:
NOVEL RISK FACTOR AND POTENTIAL EARLY DETECT MARK OVARIAN CANCER
新的风险因素和潜在的早期检测马克卵巢癌
  • 批准号:
    7201102
  • 财政年份:
    2005
  • 资助金额:
    $ 7.39万
  • 项目类别:
HORMONE METABOLISM AND BREAST MASSES
激素代谢和乳房质量
  • 批准号:
    7201154
  • 财政年份:
    2005
  • 资助金额:
    $ 7.39万
  • 项目类别:
Planning Grant for a Study of the Effect of Radiation
辐射影响研究规划拨款
  • 批准号:
    6943252
  • 财政年份:
    2005
  • 资助金额:
    $ 7.39万
  • 项目类别:
Ovarian Cancer: Prevention and Its Recurrence
卵巢癌:预防及其复发
  • 批准号:
    7124957
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
The Role of Prolactin in Postmenopausal Breast Cancer
催乳素在绝经后乳腺癌中的作用
  • 批准号:
    6948505
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
Ovarian Cancer: Prevention and Its Recurrence
卵巢癌:预防及其复发
  • 批准号:
    6838458
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
Hormone Metabolism and Breast Masses
激素代谢和乳房肿块
  • 批准号:
    6974754
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了